Stock NKTX NKARTA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Nkarta, Inc.

Equities

NKTX

US65487U1088

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
5.91 USD +0.85% Intraday chart for Nkarta, Inc. +7.45% -10.45%
06-27 Nkarta Initiates Trial of Cell Therapy to Treat Lupus Nephritis; FDA Clears Second Application MT
06-27 Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications CI

Evolution of the average Target Price on Nkarta, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c4014cb7c917fd6.bhAMaid6FHAvhKwFnCFg31poRnUeeF21jSoWlsaNKa4.Cn97IxUQJRpn0N9ssVckjgJfCRJtMzfvzH9V0rfpGsUvX30NfwpjIEfeww~96fadfbdf3981a2a9c5f101c5095f775

Analyst Recommendations on Nkarta, Inc.

Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating MT
Mizuho Securities Lowers Price Target on Nkarta to $25 From $31, Keeps Buy Rating MT
Mizuho Securities Cuts Price Target on Nkarta to $25 From $31, Maintains Buy Rating MT
HC Wainwright Adjusts Nkarta's Price Target to $20 From $22, Keeps Buy Rating MT
Raymond James Downgrades Nkarta to Outperform From Strong Buy, Price Target is $16 MT
Mizuho Securities Adjusts Price Target on Nkarta to $31 From $9 as Lupus Nephritis Program Gets Attention, Keeps Buy Rating MT
Mizuho Securities Cuts Nkarta's Price Target to $9 From $15, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Nkarta to $10 From $16, Keeps Buy Rating MT
Raymond James Upgrades Nkarta to Strong Buy From Outperform, Price Target is $13 MT
Mizuho Adjusts Nkarta's Price Target to $15 From $26, Keeps Buy Rating MT
Raymond James Adjusts Price Target on Nkarta to $13 From $32, Maintains Outperform Rating MT
Needham Cuts Price Target on Nkarta to $19 From $26, Maintains Buy Rating MT
Stifel Trims Price Target on Nkarta to $18 From $21, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Nkarta to $30 From $34, Maintains Buy Rating MT
Oppenheimer Downgrades Nkarta to Perform From Outperform, Removes $26 Price Target MT
Mizuho Slashes Price Target on Nkarta to $26 From $81, Affirms Buy Rating MT
Oppenheimer Adjusts Nkarta Price Target to $36 From $50, Maintains Outperform Rating MT
Canaccord Genuity Starts Nkarta at Buy with $25 Price Target MT
Cantor Fitzgerald Adjusts Nkarta's Price Target to $38 From $60, Reiterates Overweight Rating MT
Needham Initiates Nkarta at Buy with $26 Price Target MT
SVB Securities Initiates Coverage on Nkarta With Outperform Rating, $30 Price Target MT
Raymond James Adjusts Nkarta's Price Target to $32 From $17, Keeps Outperform Rating MT
HC Wainwright Adjusts Nkarta Price Target to $36 From $25, Maintains Buy Rating MT
Stifel Adjusts Nkarta's Price Target to $45 From $71, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.91 USD
Average target price
19.29 USD
Spread / Average Target
+226.32%
High Price Target
25 USD
Spread / Highest target
+323.01%
Low Price Target
13 USD
Spread / Lowest Target
+119.97%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nkarta, Inc.

Canaccord Genuity
HC Wainwright
Mizuho Securities
Raymond James
Needham & Co.
Stifel Nicolaus
Oppenheimer
Cantor Fitzgerald
SVB Securities LLC
William Blair & Co.
SMBC Nikko

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NKTX Stock
  4. Consensus Nkarta, Inc.